VLG logo

Venture Life Group plc Stock Price

AIM:VLG Community·UK£78.7m Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 3 Fair Values set on narratives written by author

VLG Share Price Performance

UK£0.62
0.25 (65.77%)
UK£1.00
Fair Value
UK£0.62
0.25 (65.77%)
38.2% undervalued intrinsic discount
UK£1.00
Fair Value
Price UK£0.62
AnalystConsensusTarget UK£1.00

VLG Community Narratives

AnalystConsensusTarget·
Fair Value UK£1 38.3% undervalued intrinsic discount

Midlife Preventive Health Trends Will Drive Long Term Brand Expansion

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
UK£1
38.3% undervalued intrinsic discount
Revenue
14.39% p.a.
Profit Margin
0.096%
Future PE
37.19x
Price in 2028
UK£0.01

Trending Discussion

Updated Narratives

VLG logo

Midlife Preventive Health Trends Will Drive Long Term Brand Expansion

Fair Value: UK£1 38.3% undervalued intrinsic discount
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Moderate growth potential with mediocre balance sheet.

1 Risk
1 Reward

Venture Life Group plc Key Details

UK£31.2m

Revenue

UK£16.8m

Cost of Revenue

UK£14.4m

Gross Profit

UK£15.1m

Other Expenses

-UK£693.0k

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
-0.0054
46.09%
-2.22%
30.2%
View Full Analysis

About VLG

Founded
2005
Employees
43
CEO
Jeremy Anthony Randall
WebsiteView website
www.venture-life.com

Venture Life Group plc develops and commercializes healthcare products in the United Kingdom. The company offers oral healthcare products, including mouthwash, toothpaste, breath freshening capsules, and dental accessories under UltraDEX and Dentyl Dual Action brands; and proctology products, such as Procto-eze Plus range for treating the discomfort caused by haemorrhoids. It also provides dermatology products comprising Myco Clear, a fungal nail cleanser and solution brand; Rosa calma for normalizing and controlling the signs and symptoms related to rosacea; Bioscalin for the cosmetic treatment and prevention of hair loss, hair thinning, and baldness; and skincare solutions under the brand Lubatti. In addition, the company offers women’s healthcare products, including BV treatment gel and pessaries; intimate daily wash and soothing cream; moisture gel and plus pessaries; and thrush cream under Balance Activ name. Further, it provides glucose management products, such as Lift Glucose shots and tablets for the immediate treatment of hypoglycaemia and preventing hypos; Glucogel for the treatment of hypoglycaemia. Additionally, the company offers ENT care products comprising Earol, for the removal of ear wax; EarolSwim, an invisible ear plugs for protecting the ears from water ingress; and Baby Earol, an ear spray for babies under the Earol and EarolSwim brands. It also provides oncology support products, such as Pomi-T for the management of prostate-specific antigen levels in prostate cancer; Gelclair, a muco-adhesive oral rinse for the treatment of Oral Mucositis; and Xonrid, a hyaluronic acid-based topical gel, for the prevention and treatment of radiation-induced dermatitis. The company operates in Germany, the Netherlands, France, Sweden, Denmark, Lithuania, rest of Europe, the United States, Canada, Brazil, Ireland, and internationally. Venture Life Group plc was incorporated in 2005 and is headquartered in Bracknell, the United Kingdom.

Recent VLG News & Updates

Not Many Are Piling Into Venture Life Group plc (LON:VLG) Just Yet

Nov 14
Not Many Are Piling Into Venture Life Group plc (LON:VLG) Just Yet

Recent updates

No updates